Fig. 5: Silencing PP1α impairs NY-ESO-1-mediated ERK1/2 activation and anoikis resistance.

A Immunoblot analysis of lysates from HeLa (left) and MCF-7 cells (right) stably expressing NY-ESO-1 or control, following transfection with control or PP1α siRNA for 48 h. B Immunoblot analysis of lysates from control, shNY-1 or shNY-2 stably expressing A375 cells with or without transient transfection of PP1α-flag. For (A, B), pE/G: pERK/GAPDH, pE/T: pERK/β-Tubulin, P/G: PP1α/GAPDH. C, D Representative FACS graphs (left) and statistical analysis (right) of cell death in NY-ESO-1 stably expressing MCF-7 (C), HeLa (D), and their corresponding control cells grown in suspension conditions with or without transient PP1α knockdown. **P < 0.01, ***P < 0.001, ns: not significant. E, F Representative FACS graphs (left) and statistical analysis (right) of cell death in shNY-1 or shNY-2 stably expressing A375 cells with or without indicated treatments, **P < 0.01, ***P < 0.001, ns: not significant.